Other languages Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
159.7 ^USD	+4.28%		+0.39%	+28.70%

04-22	Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung	CI
04-16	Stifel Adjusts Price Target on Krystal Biotech to $204 From $178, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung	04-22
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing	03-12
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing	03-12
Sector Update: Health Care Stocks Ease Late Afternoon	02-26
Sector Update: Health Care Stocks Weaker Monday Afternoon	02-26
Top Midday Gainers	02-26
Krystal Biotech Shares Jump After Surprise Q4 Profit	02-26
Krystal Biotech Swings to Q4 Profit as Company Generates Revenue; Shares Climb Pre-Bell	02-26
Krystal Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-26
Krystal Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-26
MORNING BID AMERICAS-Booming stocks step back as PCE hoves into view	02-26
Krystal Biotech Says FDA Grants Fast Track Designation to Inhaled KB707 for Lung Tumors Treatment	02-13
Krystal Biotech Secures J-code for Vyjuvek	01-04
Krystal Biotech Receives Permanent J-Code for VYJUVEK®	01-04
Krystal Biotech Says Japan Grants Orphan Drug Designation to Skin Disease Treatment; Shares Rise Pre-Bell	12-19
Krystal Biotech Insider Sold Shares Worth $5,283,291, According to a Recent SEC Filing	12-12
Krystal Biotech Insider Sold Shares Worth $5,283,291, According to a Recent SEC Filing	12-12
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for Vyjuvek for the Treatment of Dystrophic Epidermolysis Bullosa	11-27
Sector Update: Health Care Stocks Advance Premarket Monday	11-06
Krystal Biotech Swings to Profit in Q3; Generates Revenue	11-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Other languages

Filters